tbuckley/cabot-search huggingface dataset:
Pharmacological Inhibition of Histone Demethylase JMJD3 Reduces Leukemia Cell Survival and Represses Production of the Cytokine CCL2 in MDS/AML
Authors: Yue Wei, Yu Jia, Hong Zheng, Hui Yang, Zachary S. Bohannan, John Lee, Chong Zhao, Carlos E. Bueso-Ramos, Ali N. Chamseddine, Guillermo Garcia-Manero
Journal: Blood (2015)
Single Nucleotide Polymorphisms (SNPs) in Human Homologs of Genes Up-Regulated in the Kidney of S+S− Antilles Transgenic Mice.
Authors: Anne C. Rybicki, Vikki G. Nolan, Clinton T. Baldwin, D. F. Wyszynski, Martin H. Steinberg, Mary E. Fabry, Ronald L. Nagel
Journal: Blood (2004)
Valuation of MCP-1 and VEGF Chemokines In Serum of Patients with AL Amyloidosis
Authors: Alessandro Moscetti, Francesca Saltarelli, Maria Paola Bianchi, Guglielmo Bruno, Gerardo Salerno, Maria Teresa Corsetti, Patrizia Cardelli, Giovanna Ferranti, Giacinto La Verde
Journal: Blood (2010)
BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families
Authors: G. Piras, P. Fancello, M. Monne, M. Santona, G. Landriscina, A. Gabbas
Journal: Journal of Clinical Oncology (2006)

20118 Background: Germline alterations in the BRCA1 and BRCA2 genes highly predispose to breast and ovarian cancer. In families with BRCA1/2 mutations, identification of mutation carriers is clinically rilevant in view of the options for surveillance and prevention. The general aim of the present research is to contribute to the molecular epidemiology of BRCA1/2 genes in the italian region of Sardinia as a prerequisite for a prevention program based on DNA analysis. Methods: Fifty-two of 172 patients diagnosed with primary invasive breast carcinomas (n = 150) or ovarian cancer (n = 18) and 4 male with breast cancer referring to our departments between 2003 and 2005, had a positive family history for breast and/or ovarian cancer and were selected for BRCA1/2 mutation screening by denaturing high-performance liquid chromatography and DNA sequencing. Onehundred DNAs from healthy women originating from the same geographical area were used as population controls. Results: We identified 7 BRCA sequence alterations: 3 were already described polymorphisms while 4 novel BRCA variants were found in 11 out of 52 (21%) probands. The BRCA23951del3insAT is a novel deleterious mutation which leads to protein truncation at codon 1258 and co-occurred with the missense BRCA2S2546P in 6 probands originating from the same village and in none of the controls. Segregation analysis suggested the cis-position of the two mutations. All mutation carriers shared a common disease-associated BRCA2 haplotype indicating the presence of a founder effect. The BRCA2N272I was first observed in our population and was found in 3 unrelated probands and in none of 200 control chromosomes. The missense BRCA1E1352K mutation was present in 3 patients from two unrelated families with breast and ovarian cancer cases in three generations. Conclusions: In the present study, BRCA2 are more recurrent than BRCA1 mutations as reported for the northern part of the island. Our findings provide new epidemiological data that may be useful in defining the prevalence, mutational spectrum and penetrance of BRCA1/2 in the genetically homogeneous population of Sardinia. A comprehensive map of the BRCA mutations may facilitate screening/testing for inherited risk of breast cancer. No significant financial relationships to disclose.
Superiority of Haploidentical Related Hematopoietic Stem-Cell Transplantation Over Chemotherapy Alone for Patients with Intermediate- or Poor- Risk Acute Myeloid Leukemia in First Complete Remission,
Authors: Yingjun Chang, Honghu Zhu, Lanping Xu, Hao Jiang, Daihong Liu, Qian Jiang, Kaiyan Liu, Jin Lu, Bin Jiang, Xiaojun Huang
Journal: Blood (2011)
BCL-2/BCL-XL Inhibition in Smoldering Multiple Myeloma CD138+ Cells: Functional Effects and Protein Expression Levels
Authors: Francesco Libotte, Maria Rosaria Ricciardi, Elisabetta Calabrese, Cinzia De Benedictis, Sara Santinelli, Paola Bergamo, Samantha Decandia, Anna Levi, Ali Fathi Mohamad, Vincenzo Federico, Michele Milella, Robert Foà, Agostino Tafuri, Maria Teresa Petrucci
Journal: Blood (2008)
Survival Benefit with Decitabine Compared to Historical Experience with Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome (MDS).
Authors: Elias Jabbour, Hagop M. Kantarjian, Jorge Cortes, William G. Wierda, Alessandra Ferrajoli, Stefan Faderl, Susan O’Brien, Farhad Ravandi-Kashani, Srdan Verstovsek, Guillermo Garcia-Manero, Jan Davisson, Francis Giles, Jianqin Shan, Jean-Pierre Issa
Journal: Blood (2006)
Prognostic Factors for CMV Reactivation/Infection after Stem Cell Transplantation and Value of Oral Valganciclovir for Preemptive Therapy.
Authors: Thorsten Graef, Tatjana Bobrikova, Ortwin Adams, Roland Fenk, Leilani Ruf, Fabian Zohren, Norbert Gattermann, Rainer Haas, Guido Kobbe
Journal: Blood (2005)
Ets-2 Protein Is a Transcriptional Repressor Of The HIV-1 Virus and Acts Through Binding To The HIV-LTR-RATS Element
Authors: Ioannis Panagoulias, Tassos Georgakopoulos, Ioanna Aggeletopoulou, Fotis Karagiannis, Athanasios Skoutelis, Athanasia Mouzaki
Journal: Blood (2013)
XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia
Authors: Flavia Guillem, Michael Dussiot, Sebastien Causse, Guillaume Marcion, Emilie-Fleur Gautier, Julien Rossignol, Jean benoit Arlet, Mathilde Lamarque, Patrick Mayeux, Frederique Verdier, Xiuli An, Jean-Antoine Ribeil, Carmen Garrido, Genevieve Courtois, Narla Mohandas, Olivier Hermine
Journal: Blood (2015)
09:00–09:05Escalated Dasatinib Dose up to 60 Mg O.D. in Elderly Patients with Chronic Myeloid Leukemia in Late Chronic Phase Resistant to or Intolerant of Imatinib-12 Months Follow-up
Authors: Francesco Iuliano, Antonio Russo, Maria Cristina Caroleo, Filomena Conforti, Anna Serra
Journal: Blood (2008)
Excellent Outcome in Pediatric AML with Response Guided Chemotherapy without Allogeneic HSCT in First Complete Remission: Results from Protocol DB-AML01
Authors: Eveline de Bont, Ardine Reedijk, Tim Lammens, Valerie de Haas, Barbara Denys, Laurence Dedeken, Marry van den Heuvel, Maroeska Loo, Anne Uyttebroeck, An Vandamme, Jutte VanderWerff-ten Bosch, Jozsef Zsiros, Gertjan J.L. Kaspers, Barbara Moerloose
Journal: Blood (2015)
Non-Clinical Pharmacology of Anti-CD22 Antibody Drug Conjugates.
Authors: Dong Xie, Jakub Baudys, Pam Chan, Rong Deng, Randy Dere, Allen Ebens, Paul Fielder, Franklin Fuh, Reina Fuji, Alane Gray, Catherine Huang, Shasha Jumbe, Kathleen Makeever, Ola Saad, Jean-Philippe Stephan, Jay Tibbitts, Marna Williams, Shang-Fan Yu, Saileta Prabhu
Journal: Blood (2007)
Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells.
Authors: Renier J. Brentjens, Daniel Hollyman, Jae Park, Elmer Santos, Raymond Yeh, Jolanta Stefanski, Clare Taylor, Mark A. Weiss, Daniel Filippa, Isabelle Riviere, Michel W Sadelain
Journal: Blood (2009)
Leptomycin B Overcomes Imatinib Resistance Mediated by Stromal Cells and Mutant BCR-ABL in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Cells.
Authors: Arinobu Tojo, Kiyoko Izawa, Rieko Sekine, Tokiko Nagamura, Minoru Yoshida, Takashi Tsuji
Journal: Blood (2004)
High Efficacy of Alloantigen-Specific Induced Regulatory T Cells in the Prevention of Acute Graft-Versus-Host Disease in Mice
Authors: Jun Li, Kenrick Semple, Jessica Heinrichs, Anandharaman Veerapathran, Kelley M.K. Haarberg, Kane Koasaard, Claudio Anasetti, Xue-Zhong Yu
Journal: Blood (2012)
An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma
Authors: James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph Boccia, Donald S. Gravenor, Stephen J. Noga, Robert S Siegel, Regina A. Swift, Michael D Ehrman, Debra Bensen-Kennedy
Journal: Blood (2010)
Patient Safety Incidents Involving Sick Children in Primary Care in England and Wales: A Mixed Methods Analysis
Authors: Philippa Rees, Adrian Edwards, Colin Powell, Peter Hibbert, Huw Williams, Meredith Makeham, Ben Carter, Donna Luff, Gareth Parry, Anthony Avery, Aziz Sheikh, Liam Donaldson, Andrew Carson-Stevens
Journal: PLoS Medicine (2017)

Background The UK performs poorly relative to other economically developed countries on numerous indicators of care quality for children. The contribution of iatrogenic harm to these outcomes is unclear. As primary care is the first point of healthcare contact for most children, we sought to investigate the safety of care provided to children in this setting. Methods and Findings We undertook a mixed methods investigation of reports of primary care patient safety incidents involving sick children from England and Wales' National Reporting and Learning System between 1 January 2005 and 1 December 2013. Two reviewers independently selected relevant incident reports meeting prespecified criteria, and then descriptively analyzed these reports to identify the most frequent and harmful incident types. This was followed by an in-depth thematic analysis of a purposive sample of reports to understand the reasons underpinning incidents. Key candidate areas for strengthening primary care provision and reducing the risks of systems failures were then identified through multidisciplinary discussions. Of 2,191 safety incidents identified from 2,178 reports, 30% (n = 658) were harmful, including 12 deaths and 41 cases of severe harm. The children involved in these incidents had respiratory conditions (n = 387; 18%), injuries (n = 289; 13%), nonspecific signs and symptoms, e.g., fever (n = 281; 13%), and gastrointestinal or genitourinary conditions (n = 268; 12%), among others. Priority areas for improvement included safer systems for medication provision in community pharmacies; triage processes to enable effective and timely assessment, diagnosis, and referral of acutely sick children attending out-of-hours services; and enhanced communication for robust safety netting between professionals and parents. The main limitations of this study result from underreporting of safety incidents and variable data quality. Our findings therefore require further exploration in longitudinal studies utilizing case review methods. Conclusions This study highlights opportunities to reduce iatrogenic harm and avoidable child deaths. Globally, healthcare systems with primary-care-led models of delivery must now examine their existing practices to determine the prevalence and burden of these priority safety issues, and utilize improvement methods to achieve sustainable improvements in care quality.
Investigating Effect of Genetic Admixture and Donor/Recipient Genetic Disparity on Transplant Outcomes
Authors: Abeer Madbouly, Tao Wang, Mark Albrecht, Vanja Paunic, Michael D Haagenson, Cynthia Vierra-Green, Katharina Fleischhauer, Katharine C. Hsu, Michael R. Verneris, Navneet S. Majhail, Stephanie J. Lee, Stephen R. Spellman, Martin Maiers
Journal: Blood (2015)
Transplantation of adipose-derived stem cells combined with neuregulin-microparticles promotes efficient cardiac repair in a rat myocardial infarction model
Authors: Paula Díaz-Herráez, Laura Saludas, Simón Pascual-Gil, Teresa Simón-Yarza, Gloria Abizanda, Felipe Prósper, Elisa Garbayo, María José Blanco-Prieto
Journal: Journal of Controlled Release (2017)
Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration
Authors: Yu Ohki, Andrea Wenninger-Weinzierl, Alexander Hruscha, Kazuhide Asakawa, Koichi Kawakami, Christian Haass, Dieter Edbauer, Bettina Schmid
Journal: Molecular Neurodegeneration (2017)

The most frequent genetic cause of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) is the expansion of a GGGGCC hexanucleotide repeat in a non-coding region of the chromosome 9 open reading frame 72 (C9orf72) locus. The pathological hallmarks observed in C9orf72 repeat expansion carriers are the formation of RNA foci and deposition of dipeptide repeat (DPR) proteins derived from repeat associated non-ATG (RAN) translation. Currently, it is unclear whether formation of RNA foci, DPR translation products, or partial loss of C9orf72 predominantly drive neurotoxicity in vivo. By using a transgenic approach in zebrafish we address if the most frequently found DPR in human ALS/FTLD brain, the poly-Gly-Ala (poly-GA) protein, is toxic in vivo. We generated several transgenic UAS responder lines that express either 80 repeats of GGGGCC alone, or together with a translation initiation ATG codon forcing the translation of GA80-GFP protein upon crossing to a Gal4 driver. The GGGGCC repeat and GA80 were fused to green fluorescent protein (GFP) lacking a start codon to monitor protein translation by GFP fluorescence. Zebrafish transgenic for the GGGGCC repeat lacking an ATG codon showed very mild toxicity in the absence of poly-GA. However, strong toxicity was induced upon ATG initiated expression of poly-GA, which was rescued by injection of an antisense morpholino interfering with start codon dependent poly-GA translation. This morpholino only interferes with GA80-GFP translation without affecting repeat transcription, indicating that the toxicity is derived from GA80-GFP. These novel transgenic C9orf72 associated repeat zebrafish models demonstrate poly-GA toxicity in zebrafish. Reduction of poly-GA protein rescues toxicity validating this therapeutic approach to treat C9orf72 repeat expansion carriers. These novel animal models provide a valuable tool for drug discovery to reduce DPR associated toxicity in ALS/FTLD patients with C9orf72 repeat expansions.
Whole Genome Sequencing, Targeted Deep Sequencing and Copy-Number Analysis Provide a Comprehensive Picture of the Mutational Landscape of 41 Clinically Annotated CLL Cases
Authors: Adam Burns, Susanne Weller, Sean Humphray, Jennifer Becq, Reem Alsolami, Angela Hamblin, Ruth M Clifford, Samantha JL Knight, Pauline Robbe, Maite Cabes, Joanne Mason, Chris S.R Hatton, Jenny Taylor, David Bentley, Anna Schuh
Journal: Blood (2014)
Clinical Implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32) and -17p13 (p53) Deletions in Myeloma Patients Treated with High Dose Therapy.
Authors: Morie Abraham Gertz, Martha Q. Lacy, Angela Dispenzieri, Philip R. Greipp, Mark R. Litzow, Kim J. Henderson, Scott A. Van Wier, Gregory J. Ahmann, Rafael Fonseca
Journal: Blood (2004)
High Quality Bone Marrow Core Biopsy and Aspiration (BMBX) Procedures Can Be Performed by a Nurse Led Team Using the OnControl Battery Powered Bone Marrow Biopsy System
Authors: Chad Cherington, Ryan Robetorye, Eryn M Anderson, Trisha L Beuschel, Jody D Gunderson, Marie J Maningo-Salinas, Riccardo Valdez
Journal: Blood (2011)
Final Results From the Multicenter Compact Study of Complications in Patients with Sickle Cell Disease and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review.
Authors: Lanetta B Jordan, Patricia Adams-Graves, Julie Kanter-Washko, Patricia Ann Oneal, Francis Vekeman, Christine Bieri, Medha Sasane, Andrea Marcellari, Matthew Magestro, Zachary Gorn, Mei S. Duh
Journal: Blood (2012)
Reply
Authors: Salvatore Petta, Vincent Way‐Sun Wong, Victor de Ledinghen
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. REPLY: We recently reported that in a large cohort of patients with biopsy‐proven nonalcoholic fatty liver disease (NAFLD), controlled attenuation parameter (CAP) values by transient elastography were directly and independently linked to increased liver stiffness measurement (LSM) values using the M probe. As a consequence, we reported a progressive increase in rates of false‐positive LSM results for both F2‐F4 and F3‐F4 fibrosis from patients with CAP values in the lower tertile to those in the medium tertile and further to those in the higher tertile.1 Consistent with these data, in patients with NAFLD we suggested an algorithm for a careful LSM interpretation based on CAP values.1 We thank Dr. Karlas and colleagues for their interest in our study. We agree with the authors that both obesity and a high skin to capsule distance could lead to an overestimation of LSM in NAFLD patients and that the XL probe could potentially help to overcome these limitations. However, first, we performed our analyses in both obese and nonobese patients with a fully reliable LSM by M probe—at least 10 valid measurements taking into account LSM values and interquartile range/LSM ratio2—and, second, we have to consider that, while the M probe is in wide use, the availability of XL probe is still limited. In addition, when excluding obese NAFLD patients from our analysis, in the 131 nonobese ones with F0‐F2 fibrosis and with presumed lower skin to capsule distance we confirmed a progressive increase in LSM according to CAP tertiles (6.7 ± 3.0 versus 8.0 ± 2.9 versus 9.0 ± 5.2, P = 0.04 by analysis of variance). Finally, from a practical point of view, the CAP results are readily available in the transient elastography report, whereas skin‐to‐capsule distance and body mass index are not. Consistently, a CAP‐based interpretation would be more user‐friendly and more likely to be adopted in clinical practice. Notably, Lee and colleagues3 recently confirmed that in NAFLD patients who underwent transient elastography using the M probe, CAP values affected the diagnostic performance of LSM for fibrosis and that a CAP‐based modified reading of LSM improved its diagnostic performance. In conclusion, we are fully confident about the strength of our results and the need to validate our diagnostic algorithm in independent cohorts using both M and XL probes, the choice of one of these being also automatically recommended in the latest FibroScan software.
Subcortical Source and Modulation of the Narrowband Gamma Oscillation in Mouse Visual Cortex
Authors: Aman B. Saleem, Anthony D. Lien, Michael Krumin, Bilal Haider, Miroslav Román Rosón, Asli Ayaz, Kimberly Reinhold, Laura Busse, Matteo Carandini, Kenneth D. Harris
Journal: Neuron (2017)
TCT-526 Is There Sufficient Evidence To Discourage The Use Of Multi-Vessel Angioplasty During STEMI? An Analysis of 35,008 Patients
Authors: Sayan Sen, Darrel Francis, Ricardo Petraco, Sukhjinder Nijjer, Nicolas Foin, Rodney Foale, Nearchos Hadjiloizou, Alun Hughes, Ghada Mikhail, Iqbal Malik, Justin Davies
Journal: Journal of the American College of Cardiology (2012)
Final Report of “Korean Multicenter AML-2000 Trial”: Intention to Treat Analysis Based on Cytogenetics Risk
Authors: Yeung-Chul Mun, Jae Hoon Lee, Byoung Kook Kim, Seonyang Park, Sung-Soo Yoon, Soo-Mee Bang, Hyung Nam Moon, Deog-Yeon Jo, Chul Soo Kim, Doyeon Oh, Jae Hoo Park, Young-Don Joo, Dae Young Zang, Inho Kim, Eun Kyoung Cho, Se Hoon Park, Jung-Hye Choi, Jong Jin Seo, Young Joo Min, Hawk Kim, Moon Hee Lee, Won Sik Lee, So Young Chong, Myung Soo Hyun, Kyung Hee Lee, Hong Suk Song, Heung Sik Kim, Hyo Jin Kim, Hyuk Chan Kwon, Sung Hyun Kim, Myung Ju Ahn, Jin Seok Ahn, Yeon Hee Park, Kyung Tae Park, Hun-Mo Ryoo, Sung Hwa Bae, Hwi-Joong Yoon, Bong-Seog Kim, Seung-Hyun Nam, Thad. T Ghim, Chu-Myong Seong
Journal: Blood (2008)
Prognostic Interactions Between SRSF2, ASXL1, and IDH Mutations in Primary Myelofibrosis and Determination of Added Value to Cytogenetic Risk Stratification and DIPSS-Plus
Authors: Terra L. Lasho, Naseema Gangat, Christy Finke, Rebecca R. Laborde, Curtis A. Hanson, Rhett P. Ketterling, Ryan A. Knudson, Animesh Pardanani, Ayalew Tefferi
Journal: Blood (2012)
High Prevalence of Elderly Anemia Is Seen in a Large Inner City Outpatient Population and Is Predictive of Decreased Overall Survival across All Ethnic Groups
Authors: Anthony P Lam, Jordan Golubcow-Teglasi, Krishna Gundabolu, Howard Ratech, K. H. Ramesh, Leonidas C Platanias, Ellen Friedman, Amit Verma
Journal: Blood (2008)
Serum Erythropoietin Dose Not Participate in Anemia That Persists in CML Patients after MMR Achievement by Imatinib Mesylate Therapy
Authors: Maho Ishikawa, Fumiharu Yagasaki, Daisuke Okamura, Tomoya Maeda, Naoki Takahashi, Nobutaka Kawai, Akira Matsuda, Itsuro Jinnai, Masami Bessho
Journal: Blood (2008)
Inhibition of NF-Kb Cell Signaling and Induction of the Metastasis Suppressor and Immune Surveillance Cancer Gene RKIP Expression in B-NHL by the Novel Humanized BM-Ca Anti-CD20 Monoclonal Antibody: Implication in Chemo and Immune-Sensitization
Authors: Mario I Vega, Melisa Martinez-Paniagua, Sara Huerta-Yepez, Benjamin Bonavida
Journal: Blood (2008)
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: Outcomes Are Not Impaired in Patients of Advanced Age.
Authors: John Koreth, Julie Aldridge, Haesook T. Kim, Edwin P. Alyea, Corey Cutler, Philippe Armand, Jerome Ritz, Joseph H. Antin, Robert J. Soiffer, Vincent T. Ho
Journal: Blood (2009)
Nicotinamide Modulates Ex-Vivo Expansion of Cord Blood Derived CD34+ Cells Cultured with Cytokines and Promotes Their Homing and Engraftment in SCID Mice.
Authors: Tony Peled, Sophie Adi, Iddo Peleg, Noga G. Rosenheimer, Yaron Daniely, Arnon Nagler, Eitan Fibach, Amnon Peled
Journal: Blood (2006)
Prognosis-driven drug discovery for human colon cancer
Authors: Michael Mitas, Amanda Graham, Elizabeth Norman, Sara Strout, Craig Blum, Matt Yousefzadeh, Jessica Shrout, David Turner, Raza Hoda, Demetri Spyropoulos, Murli Krishna, Carolyn Reed, Michael Wallace
Journal: Clinical Cancer Research (2007)

A59  Treatment of colon cancer patients would benefit from the development of an accurate prognostic test that could also serve to guide therapeutic decisions. In an effort to meet this goal, we sought to i) develop a prognostic quantitative real-time RT-PCR assay using formalin fixed paraffin-embedded primary tumors, and ii), develop an assay that could be used for high throughput screening of drugs that would either abolish or restore functional activity of a viable target identified in the prognostic assay. To achieve these two objectives, we first measured the expression levels of 14 cancer-associated genes in Stage II colon cancer patients who developed disease recurrence within two years (n=9), or those who did not develop disease recurrence (n=12, mean follow-up time = 6.3 yrs). We observed that the expression ratio of (EpCAM1+Map7)/E-cadherin accurately predicted clinical outcome (Hazard ratio = 12; P=0.001 log-ranked test), such that good patient survival was associated with high expression of E-cadherin, a gene that has been shown to be downregulated by Zeb1 during colon cancer progression. Interestingly, we discovered that whereas the expression of E-cadherin was inversely correlated with Zeb1 (p=1.4E-7) in the CGAP NCI60 database, the expression of EpCAM1 was inversely correlated with Zeb2 (p=1.9E-10). We further discovered that the promoter region of EpCAM1 contained a 16 nucleotide match to the region including and surrounding the Zeb1 response element of the p73 gene (p=8.7E-7). Based on these findings, we concluded that E-cadherin represented the most viable therapeutic target of the three genes identified in the prognostic assay. To enable screening for drugs that might restore E-cadherin function, we developed a 20 microliter adhesion assay using an uncoated polystyrene surface in which it was observed that following 7 hours after cell trypsinization, the level of adhesion of highly metastatic SW620 colon cancer cell line was 15-fold (+/-4) lower compared to poorly metastatic HCT116, a cell line which we determined contains 100- and 8-fold higher levels of E-cadherin mRNA and protein, respectively, compared to SW620. This adhesion assay may allow for the identification of novel compounds that inhibit the epithelial-mesenchymal transition required for spread of metastatic disease.